Eloxx Pharmaceuticals, Inc.
Datakwaliteit: 100%
ELOX
OTC
Manufacturing
Chemicals
€ 0,08
▼
€ 0,02
(-20,08%)
Marktkapitalisatie: 405.754,0
Prijs
€ 0,08
Marktkapitalisatie
405.754,0
Dagbereik
€ 0,08 — € 0,08
52-Weeksbereik
€ 0,00 — € 0,75
Volume
12
Openen € 0,08
50D / 200D Gem.
€ 0,04
113,33% above
50D / 200D Gem.
€ 0,01
751,06% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -6,33 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,24
Interest CoverageN/A
Waardering
PE (TTM)
-0,07
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,1 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -6,00 M |
| ROE | N/A | ROA | -99,63% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -6,33 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,24 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | -17,84 M | Tangible Book Value | -20,05 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,07 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -1559,32% | ||
| Market Cap | 405.754,0 | Enterprise Value | 251.754,0 |
| Per Share | |||
| EPS (Diluted TTM) | -0,49 | Revenue / Share | 0,00 |
| FCF / Share | -1,25 | OCF / Share | -1,25 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 105,54% |
| SBC-Adj. FCF | -8,67 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | 0,0 | — | — | — | — |
| Net Income | -6,00 M | -36,07 M | -66,73 M | -34,58 M | -50,87 M |
| EPS (Diluted) | -0,49 | -16,65 | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -6,44 M | -34,42 M | -66,02 M | -33,46 M | -50,56 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | 14,59 M | 25,84 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Total Assets | 5,27 M | 21,12 M | 45,14 M | 26,48 M | 58,95 M |
| Total Liabilities | 17,18 M | 31,78 M | 22,76 M | 16,25 M | 22,73 M |
| Shareholders' Equity | -11,91 M | -10,66 M | 22,38 M | 10,23 M | 36,21 M |
| Total Debt | 1,00 M | 11,72 M | 11,18 M | 10,72 M | 13,94 M |
| Cash & Equivalents | 4,79 M | 19,21 M | 42,27 M | 24,67 M | 22,49 M |
| Current Assets | 5,27 M | 20,13 M | 43,48 M | 25,89 M | 57,71 M |
| Current Liabilities | 17,18 M | 23,09 M | 9,96 M | 9,84 M | 11,81 M |
{"event":"ticker_viewed","properties":{"ticker":"ELOX","listing_kind":"stock","pathname":"/stocks/elox","exchange":"OTC","country":"US"}}